Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2022 Sep 22;12:1032265. doi: 10.3389/fonc.2022.1032265

Corrigendum: TPX2 enhanced the activation of the HGF/ETS-1 pathway and increased the invasion of endocrine-independent prostate carcinoma cells

Hongqing Zhou 1,†, Mingsheng Liu 1,†,*, Tao Shao 1, Pingbo Xie 1, Shaojie Zhu 1, Wei Wang 1, Qiong Miao 1, Jiaxi Peng 1, Peng Zhang 2,*
PMCID: PMC9535463  PMID: 36212453

An author name was incorrectly spelled as Qinghong Zhou. The correct spelling is Hongqing Zhou.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES